Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

“Generally, we expect prices to crash in the range of 80 to 90% after ... Currently, two innovators are dominating the $50 ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Novo Nordisk is scheduled to report results for the third quarter on Wednesday. Here is what you need to know: NET PROFIT FORECAST: Net profit in the quarter is expected to rise 19% to 26.79 billion ...

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...